Overview

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Status:
Recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborator:

Precigen, Inc

Treatments:

Cyclophosphamide
Fludarabine